Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | CDA | P32320 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.30 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.30 |
| ▸ | BPTF | Q12830 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25480097 | 0.80 | HRH3 (0.37) | CDAMAPK1HTR6KAT2B | |
| SCHEMBL19370610 | 0.79 | OPRM1 (0.40) | CDACRBNDDB1 | |
| SCHEMBL10210914 | 0.77 | HTR2B (0.40) | HTR2BTMEM97ATML3MBTL1MAPK1 | |
| SCHEMBL10210786 | 0.75 | JAK2 (0.41) | HTR2BTMEM97ATML3MBTL1 | |
| SCHEMBL10210762 | 0.75 | JAK2 (0.41) | HTR2BTMEM97ATML3MBTL1 | |
| SCHEMBL21946382 | 0.75 | JAK2 (0.41) | HTR2BTMEM97ATML3MBTL1 | |
| SCHEMBL25122644 | 0.73 | LMNA (0.40) | CDA | |
| SCHEMBL7880701 | 0.73 | HTR2A (0.46) | HTR2BCRBNHTR2AHTR2C | |
| SCHEMBL2851425 | 0.70 | CDA (0.41) | HTR2BCDACRBNHTR2AHTR2C | |
| SCHEMBL9962295 | 0.70 | HTR2B (0.40) | HTR2BTMEM97ATML3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | HTR2B 4342/4885TMEM97 3546/4885CDA 3322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.